Introduction: Increasing morbidity and health care costs related to Clostridium difficile infection (CDI) have heightened interest in methods to identify patients who would most benefit from interventions to mitigate the likelihood of CDI.
Objective: To develop a risk score that can be calculated upon hospital admission and used by antimicrobial stewards, including pharmacists and clinicians, to identify patients at risk for CDI who would benefit from enhanced antibiotic review and patient education.
Methods: We assembled a cohort of Kaiser Permanente Northwest patients with a hospital admission from July 1, 2005, through December 30, 2012, and identified CDI in the six months following hospital admission. Using Cox regression, we constructed a score to identify patients at high risk for CDI on the basis of preadmission characteristics. We calculated and plotted the observed six-month CDI risk for each decile of predicted risk.
Results: We identified 721 CDIs following 54,186 hospital admissions-a 6-month incidence of 13.3 CDIs/1000 patient admissions. Patients with the highest predicted risk of CDI had an observed incidence of 53 CDIs/1000 patient admissions. The score differentiated between patients who do and do not develop CDI, with values for the extended C-statistic of 0.75. Predicted risk for CDI agreed closely with observed risk.
Conclusion: Our risk score accurately predicted six-month risk for CDI using preadmission characteristics. Accurate predictions among the highest-risk patient subgroups allow for the identification of patients who could be targeted for and who would likely benefit from review of inpatient antibiotic use or enhanced educational efforts at the time of discharge planning.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732790 | PMC |
http://dx.doi.org/10.7812/TPP/15-049 | DOI Listing |
Biomedicines
January 2025
Department I, Discipline of Anatomy and Embryology, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Background And Objectives: The interplay of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and infection (CDI) poses a critical clinical challenge. The resultant inflammatory milieu and its impact on outcomes remain incompletely understood, especially among vulnerable subgroups such as elderly patients, those with diabetes, and individuals with cancer. This study aimed to characterize inflammatory markers and composite inflammatory severity scores-such as Acute Physiology and Chronic Health Evaluation II (APACHE II), Confusion, Urea, Respiratory rate, Blood pressure, and age ≥ 65 years (CURB-65), National Early Warning Score (NEWS), and the Systemic Immune-Inflammation Index (SII)-in hospitalized Coronavirus Disease 2019 (COVID-19) patients with and without CDI, and to evaluate their prognostic implications across key clinical subgroups.
View Article and Find Full Text PDFJ Cancer Educ
January 2025
Department of Pharmacy, Al Rafidain University College, 10001, Baghdad, Iraq.
Chemotherapy-drug interactions (CDIs) pose significant challenges in oncology, affecting treatment efficacy and patient safety. Despite their importance, there is a lack of validated tools to assess oncologists' knowledge of CDIs. This study aimed to develop and validate a comprehensive questionnaire to address this gap and ensure the reliability and validity of the instrument.
View Article and Find Full Text PDFCommun Dis Intell (2018)
January 2025
The Kirby Institute, UNSW Sydney, Australia.
Australia is the only high-income country where trachoma has been endemic, defined as an overall trachoma prevalence in Aboriginal and Torres Strait Islander children aged 5-9 years of 5% or more. The Australian Government funds the National Trachoma Surveillance and Reporting Unit to collate and analyse trachoma prevalence data and control strategies annually. This report presents data submitted from 2014 to 2022.
View Article and Find Full Text PDFCommun Dis Intell (2018)
January 2025
Health Protection Policy and Surveillance Division, Australian Government Department of Health and Aged Care, Canberra, Australian Capital Territory, Australia.
Background And Methods: In March 2022, an outbreak of Japanese encephalitis virus (JEV) infection was identified in temperate south-eastern Australia, with detections in humans and animals. The unexpected emergence of JEV prompted a national public health response and a Communicable Disease Incident of National Significance was declared. JEV has previously only been identified in tropical north-eastern Australia in localised outbreaks.
View Article and Find Full Text PDFCommun Dis Intell (2018)
January 2025
Murrumbidgee and Southern New South Wales Local Health District, Public Health Unit, Infectious Diseases, NSW Health.
The detection of Japanese encephalitis virus (JEV) in pigs, at four piggeries in the Murray region in February 2022, prompted a public health investigation (PHI) by the New South Wales Department of Health (NSW Health) to identify people at greatest risk of infection. The PHI included three components: a vaccination clinic and accompanying clinic questionnaire; a serological investigation; and a cross-sectional study for consenting Australian-born participants who completed an extended questionnaire after receiving their serological results. The goals were to vaccinate a presumably naïve population to reduce associated risk and to understand the seroprevalence among Australian-born piggery workers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!